Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Cybersecurity ETF vs Novo Nordisk A/S — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $100.67, while Novo Nordisk A/S trades at $46 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while First Trust NASDAQ Cybersecurity ETF pays none, and First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| CIBR | NVO | |
|---|---|---|
52-Week High | $100.60 | $63.98 |
52-Week Low | $60.74 | $35.29 |
Market Cap | — | $207.85B |
Sector | — | Health |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CIBR trades at $100.86, up 0.26% today, with strong bullish momentum from moving averages but overbought RSI signals. The cybersecurity ETF has outperformed the S&P 500 by 3:1 year-to-date, benefiting from AI-driven security spending growth exceeding $300 billion in 2026. Recent institutional activity shows mixed sentiment with Bank of America reducing its stake while First Trust Advisors increased its position by 12.4%.
Outlook remains positive given cybersecurity's essential role in AI expansion, though high RSI levels suggest near-term consolidation risk. The sector's defensive growth characteristics and increasing attack surfaces provide long-term tailwinds, but concentrated tech exposure and valuation concerns warrant monitoring.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
